See more : Hersha Hospitality Trust (HT-PE) Income Statement Analysis – Financial Results
Complete financial analysis of Prelude Therapeutics Incorporated (PRLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prelude Therapeutics Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- GNCC Capital, Inc. (GNCP) Income Statement Analysis – Financial Results
- ITT Inc. (ITT) Income Statement Analysis – Financial Results
- Terminalcare Support Institute Inc. (7362.T) Income Statement Analysis – Financial Results
- Vitasoy International Holdings Limited (VTSYF) Income Statement Analysis – Financial Results
- Parker-Hannifin Corporation (0KFZ.L) Income Statement Analysis – Financial Results
Prelude Therapeutics Incorporated (PRLD)
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
Gross Profit | -1.17M | -3.04M | -2.24M | -542.00K | -382.00K | -149.00K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 103.39M | 92.89M | 86.78M | 48.18M | 24.28M | 12.62M |
General & Administrative | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
Other Expenses | 0.00 | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
Operating Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
Cost & Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
EBITDA | -131.11M | -122.22M | -112.82M | -58.22M | -27.73M | -14.83M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -132.28M | -123.54M | -113.74M | -58.76M | -28.11M | -14.98M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 10.45M | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
Income Before Tax | -121.83M | -115.44M | -111.69M | -56.93M | -27.57M | -14.68M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -8.10M | -915.00K | 335.70K | 210.14K | 295.00K |
Net Income | -121.83M | -107.34M | -110.78M | -56.93M | -27.57M | -14.68M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
EPS Diluted | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
Weighted Avg Shares Out | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
Weighted Avg Shares Out (Dil) | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
New Strong Buy Stocks for January 25th
Prelude Therapeutics Announces $25 Million Private Placement
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
Source: https://incomestatements.info
Category: Stock Reports